Digital Biomarkers

Examples of Digital Biomarkers in Neurology Trials

Posted on digi By digi

Neurology clinical trials face challenges in objectively measuring disease progression and treatment impact. Traditional assessments such as clinician-rated scales and patient-reported outcomes (PROs) can be subjective and episodic. Digital biomarkers—objective, quantifiable physiological or behavioral data collected via wearables—offer continuous, real-time insight into disease state and progression.

Click to read the full article.

Digital Biomarkers, Wearables and Digital Endpoints

Challenges in Regulatory Acceptance of Digital Biomarkers

Posted on digi By digi

Digital biomarkers—quantitative, objective physiological or behavioral data captured via digital devices—offer immense promise in clinical trials. From gait speed to heart rate variability and sleep fragmentation, these measures provide a continuous, real-world window into patient health. But turning a digital signal into a regulatory-accepted endpoint is far from straightforward.

Click to read the full article.

Digital Biomarkers, Wearables and Digital Endpoints

Comparing Digital vs Traditional Biomarkers

Posted on digi By digi

Biomarkers are critical in modern clinical development, serving as indicators of disease progression, treatment response, and patient outcomes. Historically, biomarkers have been derived from blood tests, imaging, or biopsies—requiring in-clinic visits and often invasive collection. However, with advances in wearable technology, digital biomarkers have emerged as a powerful complement, offering real-time, continuous insights into physiological and behavioral metrics.

Click to read the full article.

Digital Biomarkers, Wearables and Digital Endpoints

Industry Collaborations for Biomarker Validation

Posted on digi By digi

Digital biomarkers offer exciting potential for continuous, patient-centric data in clinical trials. However, the path to regulatory acceptance is complex. Unlike traditional biomarkers, digital endpoints often rely on proprietary devices, algorithms, and decentralized capture models. To gain regulatory confidence, validation must be robust, multi-dimensional, and reproducible across populations, settings, and devices.

Click to read the full article.

Digital Biomarkers, Wearables and Digital Endpoints

Case Study: Digital Biomarkers in Oncology Trials

Posted on digi By digi

Oncology trials have traditionally relied on clinic-based assessments and invasive tests to monitor disease progression and treatment toxicity. However, the burden on patients—many of whom are frail or immunocompromised—can be immense. Digital biomarkers captured via wearables and mobile platforms offer a new paradigm: continuous, non-invasive, real-world patient monitoring.

Click to read the full article.

Digital Biomarkers, Wearables and Digital Endpoints